MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-17-2026
Gossamer Bio Deferred Revenue 2011-2026 | GOSS
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Gossamer Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20 M | 17 M | 18.5 M |
Quarterly Deferred Revenue Gossamer Bio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 M | 23.5 M | 17.9 M | 17 M | 20.3 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24 M | 17 M | 19.9 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
86.5 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
1.85 M | - | - | $ 86.2 M |  USA |
 |
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K | USA |
 |
Nanobiotix S.A.
NBTX
|
410 K | $ 30.34 | -0.82 % | $ 286 B |  France |
 |
I-Mab
IMAB
|
563 K | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
2.68 M | $ 1.4 | -0.71 % | $ 360 M | USA |
 |
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
124 K | - | 2.54 % | $ 160 B | France |
 |
Applied Therapeutics
APLT
|
667 K | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
4.41 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
300 M | $ 95.5 | 3.83 % | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 2.92 | -0.34 % | $ 6.35 B |  Israel |
 |
Aytu BioScience
AYTU
|
339 K | $ 2.55 | -0.78 % | $ 16 M | USA |
 |
Midatech Pharma plc
MTP
|
1.3 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Advaxis
ADXS
|
165 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
643 K | $ 20.37 | -2.4 % | $ 952 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
2.62 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
1.09 M | $ 4.08 | -2.16 % | $ 436 M | USA |
 |
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
2.19 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
283 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
6.3 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
1.69 M | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
957 K | - | 1.93 % | $ 17.4 M | USA |
 |
Codiak BioSciences
CDAK
|
13 M | - | -55.98 % | $ 2.15 M | USA |
 |
Avid Bioservices
CDMO
|
39.9 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
9.8 M | - | - | $ 1.41 B | USA |
 |
InflaRx N.V.
IFRX
|
15 K | $ 1.0 | -2.91 % | $ 152 M | Germany |
 |
Immutep Limited
IMMP
|
1.29 M | $ 0.31 | -2.52 % | $ 1.08 B |  Australia |
 |
CureVac N.V.
CVAC
|
158 M | - | - | $ 867 M | Germany |
 |
Concert Pharmaceuticals
CNCE
|
2.75 M | - | - | $ 401 M | USA |
 |
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M | USA |